MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

Oncotarget · 2018 · PMC6047676 · PMID 30034629

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep=0.07so close (0.05 < p ≤ 0.1)

In stage III colon cancers, however, low expression of MACROD2 showed a poorer DFS than high expression of MACROD2, although this difference did not reach statistical significance (p=0.07; HR=1.6, 95% CI 1.0-2.7; Figure 2D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.